| Literature DB >> 33623397 |
Abiye Tigabu1, Abiyot Jember2, Temesgen Nega2, Getachew Wubishet2, Hana Misganaw2, Tigist Goshu2, Markos Negash3.
Abstract
BACKGROUND: Bacterial meningitis is a bacterial infection that causes inflammation of the membranes that surround the brain and spinal cord. The most frequent causes of bacterial meningitis are Neisseria meningitidis, Streptococcus pneumoniae, Listeria monocytogenes, and Haemophilus influenzae. This study aimed to determine bacterial meningitis and their antibiotic susceptibility patterns among adult patients.Entities:
Keywords: Gondar; adult patients; antimicrobial susceptibility pattern; bacterial meningitis
Year: 2021 PMID: 33623397 PMCID: PMC7895910 DOI: 10.2147/IDR.S296792
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Frequency of Study Participants by Age Groups, Gender and Year at University of Gondar Comprehensive Specialized Hospital, Gondar, Northwest Ethiopia, 2020
| Variables | Frequency | Percent | ||
|---|---|---|---|---|
| Socio-demographic characteristics | Age group | 18–27 | 1199 | 32.6% |
| 28–37 | 1067 | 29% | ||
| 38–47 | 682 | 18.5% | ||
| 48–57 | 360 | 9.8% | ||
| 58–67 | 214 | 5.8% | ||
| ≥ 68 | 161 | 4.4% | ||
| Sex | Male | 2052 | 55.7% | |
| Female | 1631 | 44.3% | ||
| Hospitalized status | >48 hours | 3313 | 90% | |
| <48 hours | 370 | 10% | ||
| Year of data collection | 2011 | Male | 224 | 54.8% |
| Female | 185 | 45.2% | ||
| 2012 | Male | 92 | 46% | |
| Female | 108 | 54% | ||
| 2013 | Male | 203 | 51.5% | |
| Female | 191 | 48.5% | ||
| 2014 | Male | 250 | 57.6% | |
| Female | 184 | 42.4% | ||
| 2015 | Male | 218 | 52.7% | |
| Female | 196 | 47.3% | ||
| 2016 | Male | 184 | 60.7% | |
| Female | 119 | 39.3% | ||
| 2017 | Male | 180 | 55.4% | |
| Female | 145 | 44.6% | ||
| 2018 | Male | 267 | 52.1% | |
| Female | 245 | 47.9% | ||
| 2019 | Male | 272 | 64% | |
| Female | 153 | 36% | ||
| 2020 | Male | 162 | 60.7% | |
| Female | 105 | 39.3% | ||
Figure 1Frequency and percentage of bacterial isolates at University of Gondar Comprehensive Specialized Hospital, Gondar, Northwest Ethiopia, 2020.
Bivariate and Multivariate Analysis That Shows the Relationship Between Clinical Characteristics and Prevalence of Bacterial Meningitis Among Adult Patients at University of Gondar Comprehensive Specialized Referral Hospital, Gondar, Northwest Ethiopia, 2020
| Clinical characterstics | Positive for BM | Negative for BM | COR (95% CI) | p-value | AOR (95% CI) | p-value | |
|---|---|---|---|---|---|---|---|
| Male | 33 (1.61%) | 2019 (98.39%) | 0.53 (0.283–0.993) | 0.048S | 0.528 (0.282–0.99) | 0.047S | |
| Female | 14 (0.86%) | 1617 (99.14%) | 1 | 1 | |||
| > 48 hours | 43 (1.30%) | 3270 (98.70%) | 0.831 (0.297–2.33) | 0.725 | 0.819 (0.292–2.30) | 0.705 | |
| <48 hours | 4 (1.08%) | 366 (98.92%) | 1 | 1 | |||
| 18–27 | 12 (1.00%) | 1187 (99.00%) | 1.01 (0.822–1.244) | 0.916 | 1.017 (0.827–1.25) | 0.871 | |
| 28–37 | 18 (1.69%) | 1049 (98.31%) | 1.01 (0.822–1.244) | 1.017 (0.827–1.25) | |||
| 38–47 | 9 (1.32%) | 673 (98.68%) | 1.01 (0.822–1.244) | 1.017 (0.827–1.25) | |||
| 48–57 | 4 (1.11%) | 356 (98.99%) | 1.01 (0.822–1.244) | 1.017 (0.827–1.25) | |||
| 58–67 | 3 (1.40%) | 211 (98.56%) | 1.01 (0.822–1.244) | 1.017 (0.827–1.25) | |||
| ≥ 68 | 1 (0.62%) | 160 (99.38%) | 1 | 1 | |||
Note: s=statistically significant.
Abbreviations: BM, bacterial meningitis; COR, crude odds ratio; AOR, adjusted odds ratio; CI, confidence interval.
Figure 2Trends of bacterial meningitis by years at University of Gondar Comprehensive Specialized Hospital, Gondar, Northwest Ethiopia, 2020.
Antimicrobial Susceptibility Profile of Gram-Positive Bacterial Isolates at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, from January to August, 2020
| Antibiotics | Coagulase Negative Staphylococci | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | |
| Ampicillin | 6 (100) | 0 (0) | N/A | N/A | 1 (33.3) | 2 (66.7) | N/A | N/A | 1 (100) | 0 (0) |
| Ceftriaxone | 6 (100) | 0 (0) | N/A | N/A | 3 (100) | 0 (0) | 1 (100) | 0 (0) | 1 (100) | 0 (0) |
| Chloramphenicol | 7 (77.8) | 2 (22.2) | 0 (0) | 1 (100) | 0 (0) | 1 (100) | N/A | N/A | 1 (100) | 0 (0) |
| Ciprofloxacin | 5 (83.3) | 1 (16.7) | N/A | N/A | 2 (66.7) | 1 (33.3) | N/A | N/A | N/A | N/A |
| Gentamicin | 1 (25) | 3 (75) | 0 (0) | 1 (100) | N/A | N/A | N/A | N/A | 1 (100) | 0 (0) |
| PencillinG | 11 (100) | 0 (0) | 0 (0) | 1 (100) | 1 (50) | 1 (50) | 1 (100) | 0 (0) | N/A | N/A |
| Cotrimoxazole | 2 (33.3) | 4 (66.7) | N/A | N/A | 0 (0) | 3 (100) | 1 (100) | 0 (0) | N/A | N/A |
| Amoxicillin | 3 (100) | 0 (0) | N/A | N/A | 2 (66.7) | 1 (33.3) | N/A | N/A | 1 (100) | 0 (0) |
| Norfloxacin | 3 (100) | 0 (0) | N/A | N/A | 1 (100) | 0 (0) | N/A | N/A | N/A | N/A |
| Vancomycin | 7 (87.5) | 1 (12.5) | 1 (100) | 0 (0) | 2 (66.7) | 1 (33.3) | 1 (100) | 0 (0) | 1 (100) | 0 (0) |
| Clindamycin | N/A | N/A | N/A | N/A | 3 (100) | 0 (0) | N/A | N/A | 1 (100) | 0 (0) |
| Cefoxitin | 2 (100) | 0 (0) | N/A | N/A | 3 (100) | 0 (0) | N/A | N/A | N/A | N/A |
| Tetracycline | 3 (42.9) | 4 (57.1) | N/A | N/A | 1 (33.3) | 2 (66.7) | 0 (0) | 1 (100) | N/A | N/A |
| Erythromycin | 4 (80) | 1 (20) | N/A | N/A | 4 (66.7) | 2 (33.3) | 0 (0) | 1 (100) | N/A | N/A |
| Cefuroxime | 1 (100) | 0 (0) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Kanamycin | 1 (100) | 0 (0) | N/A | N/A | N/A | N/A | N/A | N/A | 1 (100) | N/A |
Abbreviations: S, sensitive; R, resistant; NLF, non-lactose fermenter; N/A, not applicable.
Antimicrobial Susceptibility Profile of Gram-Negative Bacterial Isolates at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, from January to August, 2020
| Antibiotics | NLF Gram-Negative Rods | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | S (%) | R (%) | |
| Ampicillin | 0 (0) | 5 (100) | 1 (100) | 0 (0) | 1 (50) | 1 (50) | 0 (0) | 3 (100) | 0 (0) | 1 (100) | 1 (100) | 0 (0) | 1 (100) | 0 (0) |
| Ceftriaxone | 3 (100) | 0 (0) | 3 (75) | 1 (25) | 2 (100) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | 1 (100) | 1 (100) | 0 (0) | 1 (50) | 1 (50) |
| Chloramphenicol | 2 (50) | 2 (50) | 1 (100) | 0 (0) | 1 (100) | 0 (0) | 1 (100) | 0 (0) | N/A | N/A | 1 (100) | 0 (0) | 1 (100) | 0 (0) |
| Ciprofloxacin | 3 (60) | 2 (40) | 2 (67) | 1 (33) | 3 (75) | 1 (25) | 2 (100) | 0 (0) | 1 (100) | 0 (0) | N/A | N/A | 2 (66.7) | 1 (33.3) |
| Gentamicin | 4 (67) | 2 (33) | 0 (0) | 1 (100) | 2 (67) | 1 (33) | 1 (33) | 2 (67) | N/A | N/A | 1 (100) | 0 (0) | 1 (50) | 1 (50) |
| PencillinG | N/A | N/A | 2 (67) | 1 (33) | N/A | N/A | 1 (100) | 0 (0) | N/A | N/A | N/A | N/A | N/A | N/A |
| Cotrimoxazole | 3 (100) | 0 (0) | 3 (100) | 0 (0) | 1 (33) | 2 (67) | 0 (0) | 2 (100) | N/A | N/A | 1 (100) | 0 (0) | 1 (50) | 1 (50) |
| Amoxicillin | 0 (0) | 1 (100) | 3 (100) | 0 (0) | 1 (100) | 0 (0) | N/A | N/A | N/A | N/A | 1 (100) | 0 (0) | 1 (100) | 0 (0) |
| Norfloxacin | 0 (0) | 1 (100) | 2 (100) | 0 (0) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Vancomycin | N/A | N/A | 1 (100) | 0 (0) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Clindamycin | N/A | N/A | 1 (100) | 0 (0) | N/A | N/A | 1 (100) | 0 (0) | N/A | N/A | N/A | N/A | N/A | N/A |
| Cefoxitin | N/A | N/A | 1 (50) | 1 (50) | N/A | N/A | N/A | N/A | 0 (0) | 1 (100) | N/A | N/A | N/A | N/A |
| Meropenem | 1 (100) | 0 (0) | 1 (100) | 0 (0) | 1 (100) | 0 (0) | N/A | N/A | N/A | N/A | N/A | N/A | 0 (0) | 1 (100) |
| Tetracycline | 3 (100) | 0 (0) | 3 (100) | N/A | N/A | 0 (0) | 2 (100) | N/A | N/A | N/A | 0 (0) | 1 (100) | 1 (100) | 0 (0) |
| Erythromycin | N/A | N/A | 3 (100) | 0 (0) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Imipenem | N/A | N/A | N/A | N/A | 1 (100) | 0 (0) | N/A | N/A | 1 (100) | 0 (0) | N/A | N/A | N/A | N/A |
| Cefuroxime | N/A | N/A | N/A | N/A | 1 (100) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | 1 (100) | N/A | N/A | 0 (0) | 1 (100) |
| Tobramycin | N/A | N/A | N/A | N/A | N/A | N/A | 0 (0) | 1 (100) | N/A | N/A | N/A | N/A | 0 (0) | 1 (100) |
| Ceftazidime | N/A | N/A | N/A | N/A | 2 (100) | 0 (0) | N/A | N/A | N/A | N/A | N/A | N/A | 0 (0) | 1 (100) |
Abbreviations: S, sensitive; R, resistant; NLF, non-lactose fermenter; N/A, not applicable.
Multidrug-Resistant Patterns for Gram-Positive and Gram-Negative Bacteria at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, from January to August, 2020
| Bacterial Isolate | R3 | R4 | Greater Than 4 | Frequency |
|---|---|---|---|---|
| 1 | 0 | 0 | 1 | |
| 1 | 0 | 0 | 1 | |
| 0 | 0 | 2 | 2 | |
| 0 | 0 | 0 | 0 | |
| CoNS | 1 | 0 | 0 | 1 |
| 1 | 1 | 0 | 2 | |
| 2 | 2 | 0 | 4 | |
| 1 | 0 | 0 | 1 | |
| NLFGNR | 0 | 0 | 1 | 1 |
| 0 | 0 | 0 | 0 | |
| 1 | 0 | 1 | 2 | |
| 0 | 0 | 0 | 0 | |
| Total | 8 | 3 | 4 | 15 |
Abbreviations: R3, resistance to 3 drug classes; R4, resistance to 4 drug classes; >4, resistance to greater than 4 drug classes.